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Abstract
Klippel-Trenaunay syndrome (KTS) is a rare congenital disease, characterized by a triad of clinical features: (1) 
capillary malformations, manifesting as a “port wine stain”, (2) vascular anomalies, mostly varicose veins and (3) 
bone and/or soft tissue hypertrophy, usually of one lower extremity. The symptoms are frequently accompanied 
by lymphatic abnormalities that in some cases may lead to lymphedema. KTS is mostly benign in the course. 
Nevertheless, patients with KTS are at higher risk of developing deep vein thrombosis (DVT), pulmonary throm-
boembolism, recurrent episodes of thrombophlebitis, dermatolymphangitis or internal bleeding. Management 
in KTS should be individualized, minimally invasive and involve multidisciplinary care of the patient. We report 
a case of a man with fully symptomatic KTS, after incident pulmonary thromboembolism in the past and with 
severe phlebolymphedema, effectively treated with decongestive lymphatic therapy (DLT). We also provide 
a review of the literature on the clinical aspects of this complex syndrome.
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Introduction
Klippel-Trenaunay syndrome (KTS) is an unusually seen 
congenital vascular disorder, mostly occurring sporad-
ically and characterized by a triad of presentations: (1) 
capillary malformations, manifesting as a “port wine 
stain”, (2) vascular anomalies, mostly varicose veins 
and (3) bone and/or soft tissue hypertrophy of usually 
one lower extremity. 
The diagnosis of KTS is mostly made clinically when 
at least two of these features are present [1, 2]. Char-
acteristic clinical symptoms are usually noticed during 
infancy or in early childhood [1–4]. Lymphatic malfor-
mations and abnormal lymphatic drainage are present in 
the majority of patients [2, 5]. In some cases, lymphatic 
disorders may lead to lymphedema [6]. Because of 
difficulties in recognition of lymphatic abnormalities, 
they might have been under-reported in many studies. 
KTS is mostly benign in the course. Nevertheless, it 
associates with a higher risk of developing deep venous 
thrombosis, pulmonary thromboembolism, superficial 
thrombophlebitis, recurrent dermatolymphangitis or 
internal bleeding [3, 7–9].
Management in KTS requires a multidisciplinary 
approach including careful diagnosis, prevention and 
treatment of complications. 
We present a case of a 56-year-old patient with fully 
symptomatic KTS, after incident pulmonary thrombo-
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embolism in the past and with severe phlebolymphede-
ma, effectively treated with decongestive lymphatic 
therapy (DLT).
Case report
56-year-old men were admitted to the Department of 
Internal Medicine in the 4th Military Hospital in Wroclaw 
due to the right lower limb edema. The patient was 
complaining about increasing discomfort, heaviness, 
swelling, ulceration and increasing lymphorrhoea within 
the right lower extremity. Lymphedema had appeared 
in the patient at the age of 30 and gradually increased. 
Medical history of the patient was also relevant for 
arterial hypertension, deep vein thrombosis of the 
right lower limb and the pulmonary thromboembolism 
diagnosed 8 years earlier. The patient has been on 
chronic anticoagulation (acenocumarol) as secondary 
prophylaxis of deep vein thrombosis. 
During physical examination, the following abnor-
malities within the right lower extremity were found: 
hypertrophy of the limb, large flat cutaneous capillary 
malformation (port wine stain) extending to the ab-
dominal skin, severe phlebolymphedema, numerous 
varicose veins and skin lesions secondary to venous and 
lymphatic insufficiency, including hyperpigmentation, 
thickening and keratosis of swollen skin and minor 
ulceration on the calf (Fig. 1A–C). 
Laboratory examination showed mild normocytic 
anemia (hemoglobin level 13.2 g/dL; normal range > 
14.0 g/dL) and slightly elevated D-dimer level (0.92 
ug/mL; normal range < 0.50 ug/mL). ECG revealed 
right bundle branch block. Echocardiography showed 
moderate aortic, tricuspid and pulmonary regurgita-
tion, right atrial and ventricular enlargement due to 
atrial septal defect with left to right shunt, without 
evidence of pulmonary hypertension (RVSP 22 mm Hg). 
Lymphoscintigraphy revealed numerous lymphatic 
malformations and cutaneous lymph stasis within the 
right lower extremity (Fig. 2). Doppler ultrasound of 
the lower limbs showed the insufficiency of the right 
saphenous vein, numerous varicose veins and an ar-
teriovenous fistula located on the medial side of the 
right knee joint. Computed tomography angiography 
(angio-CT) confirmed the presence of the arterio-
venous fistula: it revealed a small arterial vessel with 
a diameter of approximately 0.2 cm, originating from 
the right femoral artery, approximately 15.0 cm above 
the right knee joint, and supplying the right saphenous 
vein, approximately 2.5 cm below the right knee joint 
and causing it to widen to a diameter of about 1.0 cm 
in the whole further course.
During the next hospitalization, the patient un-
derwent arteriography with embolization of the 
arteriovenous fistula with histoacryl glue with a good 
clinical effect. Arteriography also showed numerous 
micro-arteriovenous fistulas within the right lower 
extremity. The treatment of phlebolymphedema 
consisted of decongestive lymphatic therapy (DLT), 
involving the following components: multilayer short-
stretch compression bandages, manual lymphatic 
drainage (MLD), sequential intermittent pneumatic 
compression (SIPC), skin care, and decongestive 
exercises. It resulted in significant edema reduction, 
improvement of the skin condition of the lower limb, 
including healing of the ulcer, and reduction of pre-
viously reported symptoms, such as discomfort and 
heaviness of the right leg. The patient requires regular 
follow-up visits.
Figure 1. Clinical features of KTS within right lower extremity in our patient: limb hypertrophy, port wine stain, phlebolymphe-
dema, large varicose veins and skin lesions secondary to venous and lymphatic insufficiency; A — front view; B —  side view; 
C — back view
A B C
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Discussion
KTS in the literature is known by various names, 
including angioosteohypertrophy syndrome or capil-
lary-lymphaticovenous malformation [3, 10, 11]. The 
first case was reported in 1900 by Maurice Klippel and 
Paul Trenaunay [12]. 
KTS affects men and women in all ethnic groups 
equally [13]. The aetiology of the syndrome remains 
unknown and many theories have been proposed. It is 
generally accepted that KTS is a congenital disorder, in 
which blood and lymph vessels do not properly form 
during intrauterine development [11, 14–16]. KTS 
is postulated to be the result of sporadic mutations, 
including chromosomal translocations such as: t(5;11)
(q13.3;p15.1) [17, 18] or t(8;14)(q22.3;q13) [19], su-
pernumerary ringed chromosome 18 [20], mutations 
in the PIK3CA gene [21], and somatic mutations in 
RASA 1 gene [22–24]. Other possible theories deal with 
embryonic disturbed vasculogenesis [25, 26], mesoder-
mal defects or somatic mosaicism of a dominant lethal 
gene [27]. Nevertheless, none of the hypotheses could 
explain the entire manifestation of KTS.
The spectrum of clinical features in KTS is wide 
[2, 3, 28, 29]. Typically, the syndrome affects unilaterally, 
however, the involvement of all 4 extremities have also 
been reported [1, 30]. In the study of 252 patients with 
KTS, port wine stain was found in 98%, varicose veins 
or venous malformations in 72% and limb hypertrophy 
in 67%. All three features of KTS were present in 63% 
of patients, and 37% had 2 of them [1].
The capillary malformations, commonly called “port 
wine stain”, manifest as red to purplish geographic dis-
colourations on the skin. The port wine stain is usually 
located on the affected limb, however, it may be present 
in any area of the body [6, 30, 31]. Present at birth, the 
port wine stain is usually flat and will not regress. Later, 
it can become studded with vascular nodules and its 
colour may decrease [4]. Dermatopathological, it con-
sists of many vascular channels lined by a single layer of 
endothelial cells localized on the surface of the skin [4]. 
The term “hemangioma” for the port wine stain is 
incorrect because the vessels in KTS are remodelled 
and incorrectly formed. The port wine stain remains 
the same size, whereas, in blood vessel tumours, the 
endothelial cells grow excessively [32, 33]. 
Asymmetric enlargement of the affected extremity 
can include long bones elongation, soft tissue hyper-
trophy and, less commonly, muscular hypertrophy, 
accompanied by increasing skin thickness and vascular 
tissue [2]. Soft tissue enlargement can be localized or 
spreading along the entire limb, sometimes reaching 
the trunk [28]. In the majority of cases, hypertrophy 
involves one limb (in 80-85% of cases) [4, 6, 30], 
usually lower extremity. However, cases with affected 
two up to four limbs have been also reported [30, 31]. 
Significant limb-length discrepancy (greater than 
2 cm) that requiring surgical intervention is estimated 
at 14 % of all cases [32]. The severity of hypertrophy is 
unpredictable and varies widely among individuals [2]. 
Polydactyly, syndactyly and macrodactyly are also rel-
atively common [1, 6, 30].
Figure 2. Lymphoscintigraphy demonstrating numerous lymphatic malformations (marked with arrows)
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Venous anomalies can involve both the superficial 
and deep venous system. Tortuous superficial varicose 
veins are the most common manifestation, as a result 
of venous hypertension [34] and abnormal drainage. 
The main factors are valvular incompetence, venous 
obstruction, vein insufficiency, hypoplasia, aplasia, and 
venous aneurysm of deep veins [3, 35, 36]. Varicosi-
ties usually occur along the lateral side of the affected 
extremity [12, 23].
Persistent embryonic veins, such as the lateral mar-
ginal vein (“vein of Servelle”, “Klippel-Trenaunay vein”) 
and the persistent sciatic vein are characteristic for KTS. 
The prevalence rate of these veins is estimated from 9% 
to 68% [1, 2, 15, 16, 21, 26, 30]. The lateral vein starts 
from a dorsal venous, runs along the lateral side of the 
lower limb, and attaches to the profunda femoris vein, 
the superficial femoral vein, the popliteal vein, the inter-
nal vein via gluteal veins, or the external iliac vein [15]. 
The persistent sciatic vein is a deep vein originating from 
the popliteal fossa, running along the sciatic nerve and 
terminating in the internal iliac vein [26, 37].
Venous malformations in KTS are commonly associ-
ated with lymphatic abnormalities [5, 36]. In the litera-
ture, the prevalence rate of the lymphatic component in 
KTS has widely ranged from 10% to 84% [1, 6, 32, 36] 
and it is frequently underestimated [4, 5]. It has been 
shown that lymphatic anomalies may be observed also 
in asymptomatic individuals if appropriate imaging tests 
are used (e.g. lymphangiography, lymphoscintigraphy, 
MRI, CT) [4]. In a study by Liu et al., the coexistence 
of lymphatic and venous malformations were found 
in almost all (in 31 of 32) patients [5]. Lymphatic mal-
formations in KTS may be macrocytic and microcystic 
[3, 5]. Patients with microcystic lymphatic anomalies 
have asymmetry in the inguinal lymph nodes, seen as ir-
regularities in outline, heterogeneity in texture, increase 
or decrease in number and size, or even absence of the 
lymph nodes [5]. Microcystic lymphatic malformation 
includes aplasia, hypoplasia or hyperplasia of lymph 
vessels. All abnormalities described above can lead 
to lymphatic outflow insufficiency and deep lymphatic 
system congestion. Reduced flow and stasis of lymph 
result in accumulation of proteins, glycosaminoglycans, 
and cellular metabolites within the skin and subcu-
taneous tissues. The raising tissue osmotic pressure 
results in the fluid gathering and, in consequence, the 
formation of edema or cutaneous lymphatic vesicles [2, 
38]. Reflux of chyle contributes to lymphorrhea (lymph 
leakage). Patients with abnormal lymphatic drainage are 
at higher risk of recurrent dermatolymphangitis and 
bacteriemia [3, 6]. 
In 1957, Servelle et al. [36, 39] made a hypothesis 
that lymphatic abnormalities in KTS occur as a conse-
quence of the obstruction of the anomalous deep veins 
The lymphatic system has a strong structural and func-
tional relationship with the venous system. According 
to a centrifugal theory of lymphangiogenesis, that the 
primitive lymph sacs originate from embryonic veins, 
the lymphatic malformations may arise as a result of 
the vascular anomalies. 
Patients with KTS complain mostly about pain, ede-
ma, the heaviness of the limb, and movement difficul-
ties. Vascular anomalies can lead to such complications 
as bleeding, thrombophlebitis, cellulitis, ulcerations 
[2, 16, 30]. They are the main reason for seeking 
medical help.
KTS associates with a higher risk of developing 
serious complications as deep vein thrombosis (DVT), 
pulmonary embolism (PE), congestive heart failure, 
and recurrent internal bleeding from abnormal ves-
sels in the gastrointestinal tract, kidney and genitalia 
[2, 6, 8, 14, 21, 41, 42]. Heart defects are also common 
presentations [41, 43]. 
The relationship between large venous abnormali-
ties and hypercoagulability have been documented but 
the exact pathomechanism requires further study. In 
the theory of “localized intravascular coagulation” (LIC) 
proposed by Mazoyer et al. [44], vascular anomalies 
cause blood stagnation. As a result, blood stagnation 
within the deformed, slow-flow venous channels gener-
ates consumption of coagulation factors and cause the 
formation of thrombin and fibrin. Laboratory evidence 
of LIC process includes elevated D-dimer level, pro-
longed prothrombin time, decreased fibrinogen level, 
and moderately low platelet count. The larger and more 
complex vascular malformation, the higher the risk for 
thromboembolic events [7, 44]. Deep vein thromboses 
can lead to chronic thromboembolism and recurrent 
pulmonary embolism [9]. It is worth noticing that LIC 
can progress to disseminated intravascular coagulation 
(DIC) under acute systemic conditions, such as sepsis, 
surgery, neoplasm, pregnancy, trauma, prolonged im-
mobility, or even menstruation [7, 44].
The diagnosis of Klippel-Trenaunay syndrome is 
primarily clinical, based on an interview, past history, 
current patient’s complaints and physical examination. 
Imaging tests, including Duplex ultrasonography, mag-
netic resonance imaging (MRI), computed tomography 
(CT), lymphoscintigraphy, standard radiography are 
useful to confirm the diagnosis and evaluate the severity 
of the disease and its complications [1, 2, 32].
KTS should be distinguished from Parkes-Weber 
syndrome (PWS). Despite many similarities in the 
clinical features, the diseases are different in terms of 
aetiology, course and prognosis [32, 33, 45]. PWS is 
distinguishable from KTS primarily by the presence of 
one or more hemodynamically significant arteriovenous 
fistulas. Due to the presence of the high-flow arterio-
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venous fistula, the treatment and prognosis of PWS vary 
greatly in comparison to KTS and these two entities 
should by considered as different diseases [2, 6, 11, 
15, 31, 33, 36, 46]. Patients with KTS may have arteri-
ovenous fistulas but the shunts are usually not clinically 
important [11, 15]. Moreover, lymphatic anomalies are 
uncommon in PWS and show different patterns [47].
At present, there is no causative treatment for 
KTS. Generally, management of the disease should be 
individualized and minimally invasive (1–3, 16, 28, 30, 
48]. It includes local wound and skin care, rehabilitation, 
the elevation of the limbs, compression therapy, lifestyle 
modification and psychological support [2, 21].
The decongestive lymphatic therapy (DLT) is the 
primary complex treatment for lymphedema [49–52] 
with the purpose of preventing dermatolymphangi-
tis, elephanthiasis and ulcerations. The DLT includes 
four components: (1) compression therapy with use 
of short-stretch multilayer compression bandaging, 
compression sleeves, garments, and sequential inter-
mittent pneumatic compression (SIPC), (2) manual 
lymph drainage (MLD), (3) skin and nail care, and (4) 
decongestive exercises [50].
Surgery should be considered in patients refractory 
to conservative care, in life-treating symptoms such as 
hematuria, vaginal, rectal or esophageal bleeding, or in 
cases where the limb hypertrophy leads to impairment 
[2, 27, 41]. A decision about invasive treatment of 
varicose veins, ligation, or stripping should be carefully 
considered after detailed imaging of blood and lymphat-
ic vessels [2, 16, 31, 48, 53]. Endovascular therapy and 
minimally invasive procedures (e.g. pulsed-dye laser 
treatment, sclerotherapy, ablation, embolization) are 
promising methods in the management of KTS and they 
may provide an alternative for operative interventions 
[21, 54]. Due to little treatment evidence and a large 
variety of clinical pictures of KTS, it is not possible to 
establish a clear strategic procedure for all the patients. 
Generally, it is recommended that patients with KTS 
should be treated by a multidisciplinary team of medical 
doctors, physiotherapists and psychologists [3, 16, 21].
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